Showing 2681-2690 of 4063 results for "".
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting
- 2021 ASCRS Annual Meeting Moved to Las Vegas in Julyhttps://modernod.com/news/2021-ascrs-annual-meeting-moved-to-las-vegas-in-july/2478825/The American Society of Cataract and Refractive Surgery (ASCRS) announced that the 2021 ASCRS Annual Meeting, previously scheduled to take place in San Francisco in August, is now scheduled to be held July 23–27 in Las Vegas, Nevada, at the Mandalay Bay Convention Center. “Due to the
- Gemini Therapeutics Initiates GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophyhttps://modernod.com/news/gemini-therapeutics-initiates-gem103-phase-2a-study-as-an-add-on-to-anti-vegf-therapy-for-the-treatment-of-wet-amd-patients-at-risk-for-progressive-vision-loss-due-to-macular-atrophy/2478815/Gemini Therapeutics announced the commencement of a phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD who have, or may be at risk for, macular atrophy (MA) but require ongoing anti-vascular endothelial growth factor (anti-VEGF) treatment. Topline da
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f
- Avellino Exceeds 1 Million COVID-19 Tests in 2020 and Welcomes New Executive Team Hires In 2021https://modernod.com/news/avellino-exceeds-1-million-covid-19-tests-in-2020-and-welcomes-new-executive-team-hires-in-2021/2478756/Avellino Lab USA announced that the company performed over 1 million AvellinoCoV2 COVID-19 tests since March 2020, and has further expanded the company’s executive team to drive additional development and commercial growth in 2021. Chief Scientific Officer, Nazneen Aziz, PhD, and Global Head of S
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Prevent Blindness Issues Call for Nominations for Two Awardshttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-two-awards/2478723/Prevent Blindness has issued the call for nominations for the “